Patients with end-stage renal disease (ESRD) have been reported to have up to 5 times higher risk of fractures than the general population. The causes of this increased risk are diverse. Besides the traditional risk factors for osteoporosis such as aging, patients with ESRD suffer from chronic kidney disease-mineral and bone disorder (CKD-MBD).
Traditionally patients with ESRD who develop fractures are mainly treated for their CKD-MBD with medications that target low vitamin D, high phosphate and high IPTH. Trials that look at medications for osteoporosis have conventionally excluded patients with CKD. Hence, the use of antiresorptive in the CKD population has been controversial due to lack of data.
The aims of the lecture are:
Click here for more lecture details.
To register, scan the QR code or click on the web link. Registration closes on 16 December 2020, Wednesday.
https://tinyurl.com/cpereg6jan2021
Upon registration, participants agreed to the following PGAHI Terms & Conditions.
Lecture Details
Date:6 January 2021, Wednesday
Timing:6.30 pm - 7.30 pm
Duration:60 minutes
Fees: Complimentary
Platform:Zoom Cloud Meetings
Registration Closing Date: 16 December 2020, Wednesday
Target Audience:Pharmacists
Zoom Capacity: 500
This lecture will be conducted via Zoom Cloud Meetings app. For ease of accessing the lecture, please download/update Zoom Cloud Meetings app. Details of the lecture meeting link will be sent to the successful registrants nearer the lecture date.
